pre-IPO PHARMA

COMPANY OVERVIEW

SalioGen Therapeutics has launched Gene CodingTM, a genetic medicine platform, to develop durable, broadly applicable genetic medicines, using its Exact DNA Integration TechnologyTM (EDITTM) platform. EDIT is based on the novel mammal-derived genomic engineering tool, for use in potentially curative genetic medicines. SalioGen is focused on developing therapies for more patients with inherited diseases that are beyond what is addressable with current technologies, initially focusing on inherited macular disorders and inherited lipid disorders.


LOCATION

  • Cambridge, MA, USA

  • THERAPEUTIC AREAS

  • Cardiovascular Disease
  • Gene Therapy
  • Kidney Disease
  • Liver DIsease
  • Ophthalmology
  • Rare Diseases
  • Respiratory Disease

  • WEBSITE

    https://saliogen.com/


    CAREER WEBSITE

    https://saliogen.com/join-us/


    SOCIAL MEDIA


    INVESTORS

    SymBiosis cystic-fibrosis-foundation d1-capital-partners epiq-capital-group fidelity-management-research-company gordonmd-global-investments pbm-capital rd-fund t-rowe-price-associates

    PRESS RELEASES


    Jul 20, 2022

    SalioGen Therapeutics Strengthens its Leadership Team to Advance its Gene Coding™ Platform


    Jan 6, 2022

    RD Fund Announces Series B Financing Behind SalioGen Therapeutics


    Jan 5, 2022

    SalioGen Therapeutics Closes $115 Million Oversubscribed Series B Financing to Advance Gene Coding™ – A New Category of Genetic Medicine


    Jan 5, 2022

    Cystic Fibrosis Foundation Announces Investment in SalioGen Therapeutics to Fund Genetic Therapies Research


    Nov 10, 2021

    SalioGen Therapeutics Appoints Esteemed Industry Veterans to Executive Advisory Board


    For More Press Releases


    Google Analytics Alternative